(HealthDay News) — For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is ...
Please provide your email address to receive an email when new articles are posted on . Apixaban dose reduction to 2.5 mg twice daily appeared safe after 6 months of full-dose treatment for venous ...
Please provide your email address to receive an email when new articles are posted on . Label-concordant dosing may benefit patients on dialysis with nonvalvular atrial fibrillation more than ...
In patients with non-valvular atrial fibrillation (NVAF), no significant difference was seen in the risk of ischaemic stroke/systemic embolism (IS/SE) between those ...
Among patients hospitalized for atrial fibrillation (AF) or flutter, prescription of an off-label dose of a direct oral anticoagulant (DOAC) at discharge remains relatively common, according to data ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Older adults ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results